Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV

被引：0
|
作者：
Cosentino, F. [1 ,2 ]
Dagogo-Jack, S. [3 ]
Frederich, R. [4 ]
Cannon, C. P. [5 ]
Cherney, D. Z. I. [6 ]
Mancuso, J. P. [7 ]
Wynant, W. [8 ]
Liu, J. [9 ]
Cater, N. B. [10 ]
Pratley, R. E. [11 ]
机构：
[1] Karolinska Inst, Unit Cardiol Dept Med, Stockholm, Sweden
[2] Karolinska Univ Hosp, Heart Vasc & Neuro Theme Dept Cardiol, Stockholm, Sweden
[3] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN USA
[4] Pfizer Inc, Clin Dev & Operat, Collegeville, PA USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[6] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[7] Pfizer Inc, Global Product Dev, Groton, CT USA
[8] Syneos Hlth, Biostat, Morrisville, NC USA
[9] Merck & Co Inc, Clin Res, Rahway, NJ USA
[10] Pfizer Inc, Global Med Affairs, New York, NY USA
[11] AdventHealth, Translat Res Inst, Orlando, FL USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2023年 / 197卷
关键词：
D O I：
10.1016/j.diabres.2023.110329
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF2022-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    Charbonnel, Bernard
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Essex, Margaret N.
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid A.
    Lawrence, David
    Shih, Weichung J.
    Cannon, Christopher P.
    [J]. DIABETES, 2021, 70
  • [2] Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
    Cherney, D. Z. I.
    Segar, M.
    Pandey, A.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C. -C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2925 - 2925
  • [3] Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
    Segar, M. W.
    Pandey, A.
    Cherney, D. Z. I.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Shih, W. J.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2649 - 2649
  • [4] Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV
    Dagogo-Jack, Samuel
    Frederich, Robert
    Charbonnel, Bernard
    Liu, Jie
    Cannon, Christopher P.
    Shi, Harry
    Mcguire, Darren K.
    Cherney, David
    Cosentino, Francesco
    Shih, Weichung J.
    Masiukiewicz, Urszula
    Gantz, Ira
    Pratley, Richard E.
    [J]. DIABETES, 2021, 70
  • [5] Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David
    Charbonnel, Bernard
    Mcguire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. DIABETES, 2021, 70
  • [6] Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
    Cosentino, Francesco
    Cannon, Christopher P.
    Cherney, David Z. I.
    Masiukiewicz, Urszula
    Pratley, Richard
    Dagogo-Jack, Sam
    Frederich, Robert
    Charbonnel, Bernard
    Mancuso, James
    Shih, Weichung J.
    Terra, Steven G.
    Cater, Nilo B.
    Gantz, Ira
    McGuire, Darren K.
    [J]. CIRCULATION, 2020, 142 (23) : 2205 - 2215
  • [7] Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
    Kim, Joseph M.
    Bhatt, Deepak L.
    Dagogo-Jack, Samuel
    Cherney, David
    Cosentino, Francesco
    McGuire, Darren K.
    Pratley, Richard E.
    Liu, Chih-Chin
    Cater, Nilo B.
    Frederich, Robert
    Mancuso, James P.
    Cannon, Christopher P.
    [J]. DIABETES, 2022, 71
  • [8] Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
    Lingvay, Ildiko
    Greenberg, Michelle
    Gallo, Silvina
    Shi, Harry
    Liu, Jie
    Gantz, Ira
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1640 - 1651
  • [9] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
    Pratley, R. E.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Essex, M. N.
    Lawrence, D.
    Jones, P. L. S.
    Liu, J.
    Adamsons, I. A.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
  • [10] HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
    Pratley, Richard E.
    McGuire, Darren K.
    Fu, Wei
    Cannon, Christopher P.
    Cherney, David Z. I.
    Cosentino, Francesco
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Dagogo-Jack, Samuel
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2062 - 2062
12345